Send me real-time posts from this site at my email
Zacks

Merck's (MRK) Keytruda Gets Europe Nod for Two Carcinomas

Merck's (MRK) Keytruda, in combination with Eisai's Lenvima, gets approval for treating first-line renal cell carcinoma and recurrent endometrial carcinoma in Europe.

Welcome! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue